四价登革热疫苗(TAK-003)的长期疗效与安全性:3期随机双盲安慰剂对照试验4.5年结果
这项正在进行的3期随机双盲安慰剂对照试验在8个登革热流行国家的26个中心纳入4-16岁健康参与者,按2:1随机接受两剂TAK-003或安慰剂(间隔3个月)。从首次接种至第二剂后约4.5年,TAK-003对病毒学确诊登革热的累计疫苗效力为61.2%(95%CI 56.0-65.8),对住院病毒学确诊登革热为84.1%(77.8-88.6);基线血清阴性者相应效力为53.5%(41.6-62.9)和79.3%(63.5-88.2)。
要点
- TAK-003对病毒学确诊登革热累计疫苗效力61.2%(95%CI 56.0-65.8)。
- 对住院病毒学确诊登革热累计疫苗效力84.1%(95%CI 77.8-88.6)。
- 基线血清阴性者中对DENV-1和DENV-2显示效力,对DENV-3未观察到效力。
核心结论
- TAK-003在既往暴露个体中对全部四种登革病毒血清型显示长期效力与安全性,在登革热未暴露个体中对DENV-1和DENV-2显示效力。
研究设计与样本
- 正在进行的双盲、随机、安慰剂对照3期试验,在8个登革热流行国家的26个医学与研究中心纳入4-16岁健康参与者。
- 2016年9月7日至2017年3月31日随机分配20099人(TAK-003组n=13401;安慰剂组n=6698),按2:1分层(年龄和地区)随机,接受两剂皮下注射TAK-003或安慰剂,间隔3个月。
- 20071人(男性10142人[50.5%];女性9929人[49.5%];安全性分析集)接受了TAK-003或安慰剂,18257人(91.0%)完成第二剂后约4.5年随访(TAK-003组12177/13380;安慰剂组6080/6687)。
- 通过主动发热疾病监测和发热疾病发作的RT-PCR检测识别病毒学确诊登革热;效力结局在安全性分析集和符合方案集中评估。
主要发现
- 27684次报告发热疾病中1007次为病毒学确诊登革热(安慰剂组560次;TAK-003组447次),其中188例需住院(安慰剂组142例;TAK-003组46例)。
- 对病毒学确诊登革热的累计疫苗效力为61.2%(95%CI 56.0-65.8),对住院病毒学确诊登革热为84.1%(95%CI 77.8-88.6)。
- 基线血清阴性参与者(安全性分析集)中相应效力分别为53.5%(95%CI 41.6-62.9)和79.3%(95%CI 63.5-88.2)。
- 探索性分析中,基线血清阳性参与者中对全部四种血清型显示疫苗效力;基线血清阴性参与者中对DENV-1和DENV-2显示效力,对DENV-3未观察到效力,DENV-4因发病率低无法评估。
- 试验第3部分(首次接种后约22-57个月),TAK-003组13380人中664人(5.0%)报告严重不良事件,安慰剂组6687人中396人(5.9%)报告严重不良事件;报告17例死亡(安慰剂组6例,TAK-003组11例),均未被认为与试验疫苗相关。
关键数值与推荐
- 对病毒学确诊登革热的累计疫苗效力为61.2%(95%CI 56.0-65.8)。
- 对住院病毒学确诊登革热的累计疫苗效力为84.1%(95%CI 77.8-88.6)。
- 基线血清阴性参与者中对病毒学确诊登革热效力53.5%(95%CI 41.6-62.9),对住院病毒学确诊登革热效力79.3%(95%CI 63.5-88.2)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: About half of the world's population lives in dengue-endemic areas. We aimed to evaluate the long-term efficacy and safety of two doses of the tetravalent dengue vaccine TAK-003 in preventing symptomatic dengue disease of any severity and due to any dengue virus (DENV) serotypes in children and adolescents. METHODS: In this ongoing double-blind, randomised, placebo-controlled trial, we enrolled healthy participants aged 4-16 years at 26 medical and research centres across eight dengue-endemic countries (Brazil, Colombia, Dominican Republic, Nicaragua, Panama, Philippines, Sri Lanka, and Thailand). The main exclusion criteria were febrile illness (body temperature ≥38°C) at the time of randomisation, hypersensitivity or allergy to any of the vaccine components, pregnancy or breastfeeding, serious chronic or progressive disease, impaired or altered immune function, and previous receipt of a dengue vaccine. Participants were randomly assigned 2:1 (stratified by age and region) using an interactive web response system and dynamic block assignment to receive two subcutaneous doses of TAK-003 or placebo 3 months apart. Investigators, participants, and their parents or legal guardians were blinded to group assignments. Active febrile illness surveillance and RT-PCR testing of febrile illness episodes were performed for identification of virologically confirmed dengue. Efficacy outcomes were assessed in the safety analysis set (all randomly assigned participants who received ≥1 dose) and the per protocol set (all participants who had no major protocol violations), and included cumulative vaccine efficacy from first vaccination to approximately 4·5 years after the second vaccination. Serious adverse events were monitored throughout. This study is registered with ClinicalTrials.gov, NCT02747927. FINDINGS: Between Sept 7, 2016, and March 31, 2017, 20 099 participants were randomly assigned (TAK-003, n=13 401; placebo, n=6698). 20 071 participants (10 142 [50·5%] males; 9929 [49·5%] females; safety set) received TAK-003 or placebo, with 18 257 (91·0%) completing approximately 4·5 years of follow-up after the second vaccination (TAK-003, 12 177/13 380; placebo, 6080/6687). Overall, 1007 (placebo: 560; TAK-003: 447) of 27 684 febrile illnesses reported were virologically confirmed dengue, with 188 cases (placebo: 142; TAK-003: 46) requiring hospitalisation. Cumulative vaccine efficacy was 61·2% (95% CI 56·0-65·8) against virologically confirmed dengue and 84·1% (77·8-88·6) against hospitalised virologically confirmed dengue; corresponding efficacies were 53·5% (41·6-62·9) and 79·3% (63·5-88·2) in baseline seronegative participants (safety set). In an exploratory analysis, vaccine efficacy was shown against all four serotypes in baseline seropositive participants. In baseline seronegative participants, vaccine efficacy was shown against DENV-1 and DENV-2 but was not observed against DENV-3 and low incidence precluded evaluation against DENV-4. During part 3 of the trial (approximately 22-57 months after the first vaccination), serious adverse events were reported for 664 (5·0%) of 13 380 TAK-003 recipients and 396 (5·9%) of 6687 placebo recipients; 17 deaths (6 in the placebo group and 11 in the TAK-003 group) were reported, none were considered study-vaccine related. INTERPRETATION: TAK-003 demonstrated long-term efficacy and safety against all four DENV serotypes in previously exposed individuals and against DENV-1 and DENV-2 in dengue-naive individuals. FUNDING: Takeda Vaccines. TRANSLATIONS: For the Portuguese, Spanish translations and plain language summary of the abstract see Supplementary Materials section.
引用
- Tricou V, Yu D, Reynales H, et al. Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Glob Health. 2024. PMID: 38245116. doi:10.1016/S2214-109X(23)00522-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。